May 2006

Executive Vice President for North America and President & Chief Executive Officer of AstraZeneca US Tony P. Zook

AstraZeneca US President & CEO Tony Zook with Vice President Jeffrey Bross
and Executive Director Beverley Baxter

When AstraZeneca decided to locate its US headquarters in Delaware, it was a monumental economic development win for our State.

While we were clearly interested in keeping one of Delaware's major corporations (which traces its Delaware history back through Zeneca, ICI, Stuart Pharmaceuticals and Atlas Chemical Industries, formerly Atlas Powder, a divestment of the DuPont Company), we were even more interested in being home to a company of the future.

AstraZeneca not only helps anchor Delaware's growing biotechnology industry, but also, represents the cutting edge in the discovery, development, and delivery of oncology, cardiovascular, mental health, gastrointestinal, and respiratory medicines.  As the seventh-largest employer in Delaware, AstraZeneca has a major impact not only on Delaware's economy, but also, on the life of our community.  With over 64,000 employees world-wide and 12,000 in the U.S., approximately half of those in Delaware, AstraZeneca is one of Delaware's companies which not only understands, but also, operates in the global economy in which Delaware now must compete.

Tony P. Zook became Executive Vice President for North America and President and Chief Executive Officer of AstraZeneca US on January 1, 2006, succeeding David Brennan who was named Chief Executive, AstraZeneca PLC last July. Tony will tell AstraZeneca's story, including its economic impact in Delaware and beyond, and share his vision as the new leader of AstraZeneca US.

Beverley Baxter